Although tyrosine kinase inhibitors is effective for dramatically reducing CML cells, it might be difficult to eradicate completely the CML stem cells. We aimed to clarify the safety and effects of WT1 peptide vaccination in combination with imatinib therapy for a CML patient. A 51 year-old male with CML in CP, who showed a resistance against imatinib therapy for 2.5 years, began to be treated with 9mer modified-type WT1 peptides in combination with standard dose of imatinib. Although every 2-week-administration of WT1 peptides for 22 weeks did not show definite effects on the quantification of bcr-abl transcripts, by changing the administration from every 2 weeks to 4 weeks bcr-abl transcripts decreased remarkably. After 11 months of every...
The receptor for hyaluronic acid-mediated motility (RHAMM) is a tumor-associated antigen in chronic ...
The receptor for hyaluronic acid-mediated motility (RHAMM) is a tumor-associated antigen in chronic ...
The receptor for hyaluronic acid-mediated motility (RHAMM) is a tumor-associated antigen in chronic ...
Abstract Background The optimal strategy for vaccination to induce CD8+ T cell responses against WT1...
This phase II multicentric trial investigated whether a vaccine targeting the hallmark BCR-ABL deriv...
Combining vaccination against leukaemia-derived antigens and treatment with tyrosine kinase inhibito...
Although imatinib is the standard treatment for chronic myeloid leukaemia, not all patients reach co...
Although imatinib is the standard treatment for chronic myeloid leukaemia, not all patients reach co...
Although imatinib is the standard treatment for chronic myeloid leukaemia, not all patients reach co...
Wild-type Wilms' tumor gene WT1 is expressed at a high level in hematopoietic malignancies including...
imatinibと改変型WT1ペプチドワクチンの併用療法を行ったHLA-A*24:02陽性の慢性骨髄性白血病慢性期(chronic myeloid leukemia-chronic phase;CML...
Imatinib has become standard therapy for all phases of chronic myeloid leukemia (CML). However, data...
Imatinib has become standard therapy for all phases of chronic myeloid leukemia (CML). However, data...
Imatinib has become standard therapy for all phases of chronic myeloid leukemia (CML). However, data...
Chronic myeloid leukaemia (CML) is a clonal myeloproliferative disorder resulting from a malignant t...
The receptor for hyaluronic acid-mediated motility (RHAMM) is a tumor-associated antigen in chronic ...
The receptor for hyaluronic acid-mediated motility (RHAMM) is a tumor-associated antigen in chronic ...
The receptor for hyaluronic acid-mediated motility (RHAMM) is a tumor-associated antigen in chronic ...
Abstract Background The optimal strategy for vaccination to induce CD8+ T cell responses against WT1...
This phase II multicentric trial investigated whether a vaccine targeting the hallmark BCR-ABL deriv...
Combining vaccination against leukaemia-derived antigens and treatment with tyrosine kinase inhibito...
Although imatinib is the standard treatment for chronic myeloid leukaemia, not all patients reach co...
Although imatinib is the standard treatment for chronic myeloid leukaemia, not all patients reach co...
Although imatinib is the standard treatment for chronic myeloid leukaemia, not all patients reach co...
Wild-type Wilms' tumor gene WT1 is expressed at a high level in hematopoietic malignancies including...
imatinibと改変型WT1ペプチドワクチンの併用療法を行ったHLA-A*24:02陽性の慢性骨髄性白血病慢性期(chronic myeloid leukemia-chronic phase;CML...
Imatinib has become standard therapy for all phases of chronic myeloid leukemia (CML). However, data...
Imatinib has become standard therapy for all phases of chronic myeloid leukemia (CML). However, data...
Imatinib has become standard therapy for all phases of chronic myeloid leukemia (CML). However, data...
Chronic myeloid leukaemia (CML) is a clonal myeloproliferative disorder resulting from a malignant t...
The receptor for hyaluronic acid-mediated motility (RHAMM) is a tumor-associated antigen in chronic ...
The receptor for hyaluronic acid-mediated motility (RHAMM) is a tumor-associated antigen in chronic ...
The receptor for hyaluronic acid-mediated motility (RHAMM) is a tumor-associated antigen in chronic ...